Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Opium (Opioid) Addiction Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Opium (Opioid) Addiction Overview | 10 | 1 |
| Pipeline Products for Opium (Opioid) Addiction Comparative Analysis | 11 | 1 |
| Opium (Opioid) Addiction Therapeutics under Development by Companies | 12 | 2 |
| Opium (Opioid) Addiction Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Opium (Opioid) Addiction Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Opium (Opioid) Addiction Products under Development by Companies | 19 | 1 |
| Opium (Opioid) Addiction Products under Investigation by Universities/Institutes | 20 | 1 |
| Opium (Opioid) Addiction Companies Involved in Therapeutics Development | 21 | 14 |
| Alkermes Plc | 21 | 1 |
| Aoxing Pharmaceutical Company, Inc | 22 | 1 |
| BioDelivery Sciences International, Inc. | 23 | 1 |
| Camurus AB | 24 | 1 |
| Foresee Pharmaceuticals, LLC | 25 | 1 |
| Heron Therapeutics, Inc. | 26 | 1 |
| Indivior Plc | 27 | 1 |
| INSYS Therapeutics, Inc. | 28 | 1 |
| Omeros Corporation | 29 | 1 |
| Pfizer Inc. | 30 | 1 |
| Relmada Therapeutics, Inc. | 31 | 1 |
| Teva Pharmaceutical Industries Ltd. | 32 | 1 |
| Titan Pharmaceuticals, Inc. | 33 | 1 |
| Zynerba Pharmaceuticals, Inc. | 34 | 1 |
| Opium (Opioid) Addiction Therapeutics Assessment | 35 | 10 |
| Assessment by Monotherapy Products | 35 | 1 |
| Assessment by Combination Products | 36 | 1 |
| Assessment by Target | 37 | 2 |
| Assessment by Mechanism of Action | 39 | 2 |
| Assessment by Route of Administration | 41 | 2 |
| Assessment by Molecule Type | 43 | 2 |
| Drug Profiles | 45 | 38 |
| (buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile | 45 | 1 |
| (buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile | 46 | 1 |
| (buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile | 47 | 1 |
| (buprenorphine hydrochloride + samidorphan l-malate) Drug Profile | 48 | 5 |
| buprenorphine hydrochloride Drug Profile | 53 | 2 |
| buprenorphine hydrochloride Drug Profile | 55 | 1 |
| buprenorphine hydrochloride Drug Profile | 56 | 4 |
| buprenorphine hydrochloride depot Drug Profile | 60 | 1 |
| buprenorphine hydrochloride ER Drug Profile | 61 | 2 |
| buprenorphine hydrochloride long acting Drug Profile | 63 | 1 |
| buprenorphine hydrochloride SR Drug Profile | 64 | 2 |
| cannabidiol Drug Profile | 66 | 1 |
| cannabidiol Drug Profile | 67 | 3 |
| FP-004 Drug Profile | 70 | 1 |
| naltrexone hydrochloride Drug Profile | 71 | 1 |
| naltrexone hydrochloride Drug Profile | 72 | 1 |
| OMS-405 Drug Profile | 73 | 1 |
| OMS-527 Drug Profile | 74 | 2 |
| ORP-107 Drug Profile | 76 | 1 |
| PF-5006739 Drug Profile | 77 | 1 |
| samidorphan l-malate Drug Profile | 78 | 2 |
| TA-CD Drug Profile | 80 | 1 |
| TEV-90109 Drug Profile | 81 | 1 |
| Vaccine for Opium Addiction Drug Profile | 82 | 1 |
| Opium (Opioid) Addiction Dormant Projects | 83 | 1 |
| Opium (Opioid) Addiction Discontinued Products | 84 | 1 |
| Opium (Opioid) Addiction Product Development Milestones | 85 | 13 |
| Featured News &Press Releases | 85 | 1 |
| Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder | 85 | 1 |
| Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers | 86 | 1 |
| Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers | 87 | 1 |
| Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US | 88 | 1 |
| Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence | 88 | 1 |
| Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers | 89 | 1 |
| Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers | 90 | 1 |
| Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers | 90 | 1 |
| Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence | 91 | 1 |
| Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting | 92 | 1 |
| Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence | 92 | 2 |
| Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers | 94 | 1 |
| Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine | 94 | 1 |
| Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers | 95 | 1 |
| Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film | 96 | 2 |
| Appendix | 98 | 2 |
| Methodology | 98 | 1 |
| Coverage | 98 | 1 |
| Secondary Research | 98 | 1 |
| Primary Research | 98 | 1 |
| Expert Panel Validation | 98 | 1 |
| Contact Us | 98 | 1 |
| Disclaimer | 99 | 1 |